Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ. de Wit R, et al. Among authors: herrstedt j. Eur J Cancer. 2004 Feb;40(3):403-10. Eur J Cancer. 2004. PMID: 14746859 Clinical Trial.
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. de Wit R, et al. Among authors: herrstedt j. J Clin Oncol. 2003 Nov 15;21(22):4105-11. doi: 10.1200/JCO.2003.10.128. Epub 2003 Oct 14. J Clin Oncol. 2003. PMID: 14559891 Clinical Trial.
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Warr DG, et al. Among authors: herrstedt j. J Clin Oncol. 2005 Apr 20;23(12):2822-30. doi: 10.1200/JCO.2005.09.050. J Clin Oncol. 2005. PMID: 15837996 Free article. Clinical Trial.
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ. Gralla RJ, et al. Among authors: herrstedt j. Cancer. 2005 Aug 15;104(4):864-8. doi: 10.1002/cncr.21222. Cancer. 2005. PMID: 15973669 Free article. Clinical Trial.
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F; Aprepitant Moderately Emetogenic Chemotherapy Study Group. Herrstedt J, et al. Cancer. 2005 Oct 1;104(7):1548-55. doi: 10.1002/cncr.21343. Cancer. 2005. PMID: 16104039 Free article. Clinical Trial.
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ. Hesketh PJ, et al. Among authors: herrstedt j. Support Care Cancer. 2006 Apr;14(4):354-60. doi: 10.1007/s00520-005-0914-4. Epub 2006 Feb 1. Support Care Cancer. 2006. PMID: 16450086 Clinical Trial.
Antiemetics: state of the art.
Herrstedt J. Herrstedt J. Eur J Cancer. 2009 Sep;45 Suppl 1:439-41. doi: 10.1016/S0959-8049(09)70081-4. Eur J Cancer. 2009. PMID: 19775663 No abstract available.
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group. Roila F, et al. Among authors: herrstedt j. Ann Oncol. 2010 May;21 Suppl 5:v232-43. doi: 10.1093/annonc/mdq194. Ann Oncol. 2010. PMID: 20555089 Free article. Review. No abstract available.
195 results